Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BNTC
BENITEC BIOPHARMA INC.
NASDAQ
$12.68
▲ UP 1.93% (0.24)

KEY STATISTICS

Market Cap$436.47 M
52w High$16.76
52w Low$9.85
Dividend Yield0.12%
FrequencySpecial
P/E-11.12
Volume44.99K
Shares Out.34.35M

COMPANY

LEADERSHIP

Jerel A. Banks
CHIEF EXECUTIVE
Jerel A. Banks

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 24, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
19

PRICE TARGET

Target High$25.00
Target Low$16.00
Target Median$20.50
Target Consensus$20.50

UPCOMING EARNINGS

DateSep 28, 2026
DayMonday
Rev. Est.—
SEP
28
MON

SPLIT RECORD

DATETYPERATIO
2023-07-26Reverse1:17
2020-04-15Reverse2:3
2019-11-18Reverse1:10
2018-05-02Forward1019:1000
2015-06-16Reverse1:4

PRICE

$12.68 ▲ UP 1.93% (+$0.24)
OVERLAYS
$12.40$12.60$12.809:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM12.68

About Benitec Biopharma Inc.

https://benitec.com ↗

Benitec Biopharma Inc. is a development-stage biotech company in California developing DNA-based RNA interference therapeutics, including gene therapies for muscular dystrophy and hepatitis B.

INDUSTRY

Biotechnology

A PRODUCT BENITEC BIOPHARMA INC. IS KNOWN FOR

BB-301
BB-301

BB-301 is Benitec Biopharma’s lead gene therapy in Phase 1b/2a trials for OPMD, using a "silence and replace" approach to halt faulty gene expression and provide a functional replacement.

COMPETITORS

COMPETITOR
ALNY COMPARE
ARWR COMPARE
IONS COMPARE
RCKT COMPARE
SRPT COMPARE

Revenue by Products

IconPRODUCTQ1-2021Q2-2021Q3-2021
License$55K $1K ▼$1K
Royalty$0 $0 $0
Service$0 $0 $0

Revenue by Geography

MapREGIONFY2018FY2019
AUSTRALIA$378K $14.63M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
52
LISTED HERE
10
RANKED BY POSITION SIZE
PINK
3.61% · 1.1M
VTS.AX
0.00% · 649.5K
IWM
0.01% · 525.2K
GNOM
0.32% · 23.4K
R2SC.L
0.00% · 20.9K
XRS2.DE
0.01% · 19.2K
AVSC
0.01% · 17.4K
URTY
0.00% · 839
FSEG
0.02% · 89
RTYS.L
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
81.69%
HOLDERS
99
TOP 12 OF 99 · RANKED BY POSITION SIZE
Suvretta Capital Management, LLC
11.5M sh · $122.99M
Janus Henderson Group Plc
2.9M sh · $39.29M
Franklin Resources Inc
2.6M sh · $36.33M
Adage Capital Partners Gp, L.L.C.
2.1M sh · $22.59M
Ra Capital Management, L.P.
1.9M sh · $19.7M
Nantahala Capital Management, LLC
1.4M sh · $15.32M
Blackrock, Inc.
1.2M sh · $12.63M
Vanguard Group Inc
1.2M sh · $15.82M
Infinitum Asset Management, LLC
923.0K sh · $9.83M
Empery Asset Management, LP
796.8K sh · $296K
Siren, L.L.C.
775.0K sh · $10.44M
Alyeska Investment Group, L.P.
750.0K sh · $7.99M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
BUCHI J KEVIN
Sale · 51.8K shares
2026-06-29
★
DIRECTOR
Friedman David Matthew
Purchase · 35.0K shares
2026-05-26
★
Friedman David Matthew
— · —
2026-05-22
★
DIRECTOR
Mates Sharon
Purchase · 31.5K shares
2026-01-22

MOST RECENT ANALYST GRADES

GRADE SUMMARY
MARKET OUTPERFORM 2
BUY 1
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Citizens MARKET OUTPERFORM JMP Securities MARKET OUTPERFORM Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
SLDB$10.39COMPARE
NGNE$38.63COMPARE
AUTL$2.25COMPARE
OCGN$1.34COMPARE
GALT$4.63COMPARE
QSI$0.77COMPARE